ArticleFrontiers in pharmacology2022

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier.

Brandon M Bordeau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.